Pfizer (PFE) Tops Q4 EPS by 15c, Beats on Revenue; Offers FY25 Guidance
Pfizer (NYSE: PFE) reported Q4 EPS of $0.63, $0.15 better than the analyst estimate of $0.48. Revenue for the quarter came in at $17.8 billion versus the consensus estimate of $17.28 billion.
GUIDANCE:
Pfizer sees FY2025 EPS of $2.80-$3.00, versus the consensus of $2.93. Pfizer sees FY2025 revenue of $61-64 billion, versus the consensus of $63 billion.
For earnings history and earnings-related data on Pfizer (PFE) click here.
